Mangoceuticals, Inc. (MGRX)

Nasdaq: MGRX · Services-Misc Health & Allied Services, NEC · Dallas, TX · filing with the SEC since 2022

Full chart Alerts Compare

Grade2.9

◀ Past 2.4● Present 3.1▶ Future 3.2

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Mangoceuticals, Inc.

Nine metrics read from its own filings, by tense

Headline grade

2.9/10

◀ Past2.430% of the headline

● Present3.140% of the headline

▶ Future3.230% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

2.4/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

1.8/10

Has it survived what it has been through?

6 warning events since 2022; the latest 2026-05-15.

weight 33% of this tense · 18th percentile among 11 sector filers · read for itself

From the record

Mangoceuticals, Inc.'s filings since 2022 show 6 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 4 times, the latest 2026-02-06); a late-report notice (Form NT 10-K or NT 10-Q, 2 times, the latest 2026-05-15) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

3.3/10

What has it actually done, year after year?

+270.8% a year over 4 filed years; profitable in 0 of 4.

weight 45% of this tense · 33rd percentile among 10 sector filers · read for its customers

From the record

Mangoceuticals, Inc.'s 4 filed years say what it did: revenue went from $9 thousand in fiscal 2022 to $456 thousand in fiscal 2025, up 270.8% a year; it rose in 1 of 3 years; the deepest fall was 38% from fiscal 2023 to fiscal 2025; net income was positive in 0 of 4 of those years (its annual reports).

What it rests on

revenue growth over the filed span270.8%top 5% of its family
the share of years revenue rosebottom 5% of its family
the share of filed years with a profitbottom 15% of its family
the deepest fall from a revenue peak37.7%bottom 15% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

1.7/10

How has it treated the people who own it?

SI estimate 1.7/10, confidence 35 of 100 (one part).

weight 22% of this tense · 17th percentile among 9 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the bottom 17% of 9 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 9 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Mangoceuticals, Inc.'s shareholder treatment is put at 1.7 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 17% of 9 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

3.1/1040% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

3.7/10

Is it financially healthy right now?

ROE -136%: lost 136¢ per shareholder dollar. Leverage 6%: owes 6¢ per asset dollar.

weight 33% of this tense · 37th percentile among 10 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Mangoceuticals, Inc. lost about 136 cents for every dollar of shareholders' money, and gross profitability: its products earned about 2 cents per dollar of everything the company owns. Leverage: it owed about 6 cents per dollar of assets, and net share issuance: its share count grew 408.9% over the year (the filed statements).

What it rests on

what it owes per dollar of assetstop 5% of its family
return on equitybottom 31% of its family
gross profit against assetsbottom 6% of its family
the share count against the year beforebottom 17% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

3.9/10

How strong is its position in its industry?

bottom 39% of 10 in its family; net margin -4526.8%.

weight 45% of this tense · 39th percentile among 10 sector filers · read for its customers

From the record

Mangoceuticals, Inc.'s standing among 10 graded names in its industry family: revenue of $456 thousand in fiscal 2025 ranks in the bottom 17% by size; a net margin of -4526.8% ranks in the bottom 5%; revenue growth of 270.8% a year over the last 3 filed years ranks in the top 5% (its annual reports).

What it rests on

revenue against the family$456,021bottom 17% of its family
net margin-4526.8%bottom 5% of its family
three-year revenue growth270.8%top 5% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

0.6/10

What are the people in charge doing?

SI estimate 0.6/10, confidence 35 of 100 (one part).

weight 22% of this tense · 6th percentile among 10 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the bottom 6% of 10 in its family; the record of its people begins on 2023-03-20 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 3.7 years and cannot see past it; a floor under five years is not read as years in charge.
What the record cannot read: The record of its people begins on 2023-03-20 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 3.7 years and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned: one part: officer and director changes on Form 8-K, against the people in charge, the one part on file, ranked among 10 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Mangoceuticals, Inc.'s leadership is put at 0.6 of 10 with a confidence of 35 of 100, because read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the bottom 6% of 10 in its family; the record of its people begins on 2023-03-20 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 3.7 years and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

3.2/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed

4.1/10

How much room does it have to grow?

bottom 41% of 10 in its family for room to expand.

weight 22% of this tense · 41st percentile among 10 sector filers · read for itself

From the record

Mangoceuticals, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $1 million against no long-term debt tagged leaves 9.2% of its assets as net cash, top 35% of its family; cash from operations less capital spending is -1282.9% of revenue (bottom 15%); a gross margin of 54.9% (bottom 44%) (its annual report).

What it rests on

cash less debt against assets9.2%top 35% of its family
cash from operations less capital spending against revenue-1282.9%bottom 15% of its family
gross margin54.9%bottom 44% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

2.5/10

What could actually drive growth from here?

bottom 25% of 10 in its family for growth drivers.

weight 45% of this tense · 25th percentile among 10 sector filers · read for its customers

From the record

Mangoceuticals, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 270.8% a year over the last three filed years against 270.8% over all 4, speeding up (top 35% of its family); the newest year grew -26% (bottom 5%); capital spending grew -91.8% a year (bottom 5%) (its annual reports). Mangoceuticals, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span+0.0 points a yeartop 35% of its family
the newest year's revenue growth-26.0%bottom 5% of its family
three-year growth of capital spending-91.8%bottom 5% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

3.5/10

Did its newest year beat what its own record pointed to?

bottom 35% of 10 in its family for expectations against reality.

weight 33% of this tense · 35th percentile among 10 sector filers · read for its shareholders

From the record

Mangoceuticals, Inc.'s newest year against its own record: revenue of $456 thousand in fiscal 2025 came in 91.1% below the $5 million its prior three years' pace pointed to (bottom 5% of its family); net income of $21 million against a prior three-year average of $7 million (bottom 5%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 5%) (its annual reports).

What it rests on

revenue against the prior three years' pace-91.1%bottom 5% of its family
net income against the prior three years' average-211%bottom 5% of its family
net margin against its prior averageup more than 100 pointstop 5% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton MGRX · research, not advice